Encephalitis, Tick-Borne Clinical Trial
Official title:
Open-label Phase IV Study to Investigate the Seropersistence of Tick Borne Encephalitis (TBE) Virus Antibodies After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults (Follow Up to Study 223)
The purpose of this study is to assess:
- TBE antibody persistence 24, 34, 46 and 58 months (as applicable) after the first
booster TBE vaccination with FSME-IMMUN 0.5ml given in Study 223, by means of ELISA
(IMMUNOZYM FSME IgG) and Neutralization test (NT),
- TBE antibody response to a second booster vaccination with FSME-IMMUN 0.5ml in the
present study, by means of ELISA and NT,
- Safety of FSME-IMMUN 0.5ml after the second booster vaccination.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01031537 -
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
|
Phase 2 | |
Completed |
NCT00460486 -
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
|
Phase 3 | |
Completed |
NCT00161824 -
Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR
|
Phase 3 | |
Completed |
NCT00163540 -
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)
|
Phase 4 | |
Completed |
NCT00161967 -
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
|
Phase 4 | |
Completed |
NCT00161876 -
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
|
Phase 3 | |
Recruiting |
NCT03932448 -
Fever After Tick Bite Study
|
||
Completed |
NCT00311441 -
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
|
Phase 4 | |
Completed |
NCT00161954 -
Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years
|
Phase 4 | |
Completed |
NCT00163618 -
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
|
Phase 4 | |
Completed |
NCT00840801 -
Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
|
Phase 3 | |
Completed |
NCT00452621 -
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
|
Phase 4 | |
Completed |
NCT00311493 -
Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults
|
Phase 4 | |
Completed |
NCT00161850 -
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
|
Phase 2 | |
Completed |
NCT00161889 -
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
|
Phase 2 | |
Completed |
NCT00894686 -
Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)
|
Phase 4 | |
Completed |
NCT00161746 -
Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years
|
Phase 2/Phase 3 |